^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    BTK degrader

    Related drugs:
    2d
    Relative Bioavailability of NX-5948 Tablets vs Capsules and the Effect of Covariates on the PK of NX-5948 Tablets (clinicaltrials.gov)
    P1, N=18, Recruiting, Nurix Therapeutics, Inc. | Trial completion date: Mar 2025 --> Dec 2025 | Trial primary completion date: Feb 2025 --> Nov 2025
    Trial completion date • Trial primary completion date
    |
    bexobrutideg (NX-5948)
    25d
    Effect of Phenytoin or Itraconazole on How BGB-16673 is Absorbed and Removed From the Body in Healthy Participants (clinicaltrials.gov)
    P1, N=37, Completed, BeiGene | Recruiting --> Completed
    Trial completion
    |
    itraconazole • catadegbrutinib (BGB-16673)
    1m
    A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201) (clinicaltrials.gov)
    P2, N=100, Recruiting, Nurix Therapeutics, Inc.
    New P2 trial
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    bexobrutideg (NX-5948)
    1m
    Invasive Cutaneous Mucormycosis in a Patient With Chronic Lymphocytic Leukemia on Obinutuzumab, Idelalisib, and Bruton Tyrosine Kinase Degrader: A Case Report. (PubMed, Cureus)
    We present a case of invasive cutaneous mucormycosis in an elderly man with chronic lymphocytic leukemia (CLL), who was receiving a Bruton tyrosine kinase (BTK)-targeted protein degrader trial drug (BGB-16673), obinutuzumab, a newer anti-CD20 monoclonal therapy, and idelalisib, a phosphoinositide 3-kinase inhibitor. Clinical cure was achieved with limb amputation, given the extent of disease. This case underscores the necessity of a low index of suspicion for mucormycosis on presentation, critical appraisal of the patient's risk factors, and a multimodal approach to diagnosis.
    Journal
    |
    BTK (Bruton Tyrosine Kinase)
    |
    Gazyva (obinutuzumab) • Zydelig (idelalisib) • catadegbrutinib (BGB-16673)
    2ms
    CaDAnCe-101: A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies (clinicaltrials.gov)
    P1/2, N=614, Recruiting, BeiGene | Trial completion date: Dec 2028 --> Nov 2029 | Trial primary completion date: Dec 2025 --> Nov 2026
    Trial completion date • Trial primary completion date
    |
    catadegbrutinib (BGB-16673)
    2ms
    BGB-16673-304: A Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (clinicaltrials.gov)
    P3, N=500, Recruiting, BeiGene | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Jaypirca (pirtobrutinib) • catadegbrutinib (BGB-16673)
    2ms
    A Study to Assess How Food Affects the Movement of Oral ABBV-101 Through the Body of Healthy Adult Participants (clinicaltrials.gov)
    P1, N=17, Completed, AbbVie | Active, not recruiting --> Completed
    Trial completion
    |
    ABBV-101
    2ms
    A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies (clinicaltrials.gov)
    P1, N=60, Recruiting, Accutar Biotechnology Inc | Trial completion date: Dec 2025 --> May 2026 | Trial primary completion date: Jul 2025 --> Mar 2026
    Trial completion date • Trial primary completion date
    4ms
    A Study to Assess How Food Affects the Movement of Oral ABBV-101 Through the Body of Healthy Adult Participants (clinicaltrials.gov)
    P1, N=17, Active, not recruiting, AbbVie | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    ABBV-101
    4ms
    REBELLE: Determinants of the Response to BTK Degraders (BTKd) in Double Refractory CLL (clinicaltrials.gov)
    P=N/A, N=60, Not yet recruiting, Nantes University Hospital
    New trial
    |
    BCL2 (B-cell CLL/lymphoma 2)
    5ms
    A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple-Ascending Doses of BGB-16673 in Adults With Chronic Spontaneous Urticaria (clinicaltrials.gov)
    P1, N=27, Recruiting, BeiGene | Not yet recruiting --> Recruiting
    Enrollment open
    |
    catadegbrutinib (BGB-16673)
    5ms
    CaDAnCe-303: A Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) Inhibitors (clinicaltrials.gov)
    P3, N=150, Recruiting, BeiGene | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Rituxan (rituximab) • bendamustine • catadegbrutinib (BGB-16673)